Sumatriptan‐naproxen sodium in migraine: A review - Archive ouverte HAL
Article Dans Une Revue European Journal of Neurology Année : 2024

Sumatriptan‐naproxen sodium in migraine: A review

Sumatriptan‐naproxen sodium in migraine: A review

Robyn‐jenia Wilcha
Xavier Moisset
Peter J Goadsby

Résumé

Abstract Background Varied responses to acute migraine medications have been observed, with over one‐third (34.5%) of patients reporting insufficient headache relief. Sumatriptan‐naproxen sodium, a single, fixed‐dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg, was developed with the rationale of targeting multiple putative mechanisms involved in the pathogenesis of migraine to optimise acute migraine care. Methods A narrative review of clinical trials investigating sumatriptan‐naproxen sodium for both adults and adolescents was performed in March 2024. Results Across a total of 14 clinical trials in nine publications, sumatriptan‐naproxen sodium offered greater efficacy for 2‐h pain freedom (14/14) and sustained pain‐free response up to 24 h (13/14) compared with monotherapy and/or placebo for both adult and adolescent study participants with an acceptable and well‐tolerated adverse effect profile. Clinical trial data also demonstrates the effectiveness of sumatriptan‐naproxen sodium in participants with allodynia, probable migraine, menstrual‐related migraine and those with poor responses to acute, non‐specific, migraine medication. Conclusions Multi‐mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan‐naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen‐sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations.
Fichier principal
Vignette du fichier
Suma_Naprox_EJNeuro_2024.PDF (1.3 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence
Domaine public

Dates et versions

hal-04718529 , version 1 (02-10-2024)

Licence

Domaine public

Identifiants

Citer

Robyn‐jenia Wilcha, Shazia K Afridi, Piero Barbanti, Hans Christoph Diener, Tim Patrick Jürgens, et al.. Sumatriptan‐naproxen sodium in migraine: A review. European Journal of Neurology, 2024, 31 (S2), ⟨10.1111/ene.16434⟩. ⟨hal-04718529⟩

Collections

PRES_CLERMONT ND
0 Consultations
0 Téléchargements

Altmetric

Partager

More